Lungs News and Research

RSS

Race-related differences in genetic determinants of COVID-19 severity

Researchers at the University of Iowa have identified differences in gene expression levels between African Americans and European Americans that may explain the disproportionately higher rates of coronavirus disease 2019 (COVID-19) cases and related deaths among African Americans.

11 Jun 2020

New insight could aid in the development of universal vaccines for respiratory viruses

A significant site of damage during COVID-19 infection is the lungs. Understanding how the lungs' immune cells are responding to viral infections could help scientists develop a vaccine.

11 Jun 2020

Hyperprogression to immune blockade followed by a response with cabozantinib in metastatic RCC

Volume 11, Issue 22 of @Oncotarget reported that more and more patients receive first-line treatment with immunotherapy combinations and not all patients respond in metastatic renal cell carcinoma.

10 Jun 2020

Anticardiolipin antibodies and COVID-19

A new study has shown that anticardiolipin antibodies are associated with the novel coronavirus infection or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19.

10 Jun 2020

COVID-19 mouse model could accelerate the search for treatments, vaccines

The global effort to quickly develop drugs and vaccines for COVID-19 has been hampered by limited numbers of laboratory mice that are susceptible to infection with SARS-CoV-2, the virus that causes COVID-19.

10 Jun 2020

Blood type plays role in SARS-CoV-2 infection

A new meta-analysis from Iran, available on the medRxiv preprint server, showed that the blood group A could be considered a partial risk factor for infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), whereas the blood group O may act as a protective factor; conversely, no significant associations were observed between specific blood groups and coronavirus disease (COVID-19) mortality.

10 Jun 2020

Immuno-oncology may accelerate the development of treatments for COVID-19

Researchers at Roswell Park Comprehensive Cancer Center have been actively engaged in the effort to develop treatments or other control strategies that can help communities worldwide to address the impacts of the COVID-19 pandemic.

10 Jun 2020

Undersized airways increase risk of COPD regardless of smoking habits

A new study of lung anatomy may explain why 1 in 4 cases of COPD--a lung disease most often linked to smoking--occur in people who have never smoked, a fact that has long perplexed researchers.

9 Jun 2020

COVID-19 produces lung inflammation in non-human primate experiments

A new study published on the online preprint server bioRxiv in June 2020 reports the successful use of three primate species to model the infection, pathogenesis, and clinical features associated with COVID-19. The research provides useful and immediately available models to test new vaccines and treatments.

9 Jun 2020

Metabolic diseases alter ACE2 expression and increase COVID-19 severity

A new study published on the preprint server medRxiv in June 2020 reports that one mechanism for this variable severity is the differential expression of the ACE2 receptor in various metabolic conditions, thereby facilitating viral entry into the host cells.

9 Jun 2020

Novel compound shows promise for ANCA-associated vasculitis

ANCA-associated vasculitis (AAV) is a systemic disease involving the formation of special autoantibodies (so-called anti-neutrophil cytoplasmic antibodies/ANCA) and vascular inflammation.

8 Jun 2020

Tocilizumab in COVID-19 patients on mechanical ventilation

Now, a new study by researchers from the University of Michigan and published on the online preprint server medRxiv* in June 2020 shows that the cytokine inhibitor tocilizumab could have a favorable effect on survival in the most severely infected patients who require mechanical ventilation. This needs to be confirmed by clinical trials.

7 Jun 2020

Kidney impairment significantly higher among hospitalized COVID-19 patients

Germany was not hit as hard by the SARS-CoV-2 pandemic as many other European countries. The reason for this is that the wave of infection reached Germany later, that the authorities were warned by the situation in Italy and Spain and at an early stage ordered a lockdown and conducted extensive testing.

5 Jun 2020

Sleep fragmentation associated with inflammation and atherosclerosis

Disrupted nightly sleep and clogged arteries tend to sneak up on us as we age. And while both disorders may seem unrelated, a new study from the University of California, Berkeley, helps explain why they are, in fact, pathologically intertwined.

5 Jun 2020

High uric acid levels protect against lung function decline in women

Researchers at Kumamoto University in Japan have discovered that uric acid, an antioxidant, protects against declining lung function from age or lung disease, especially in women.

5 Jun 2020

Scientists aim to develop a gene-targeting, antiviral agent against COVID-19

A team of scientists from Stanford University is working with researchers at the Molecular Foundry, a nanoscience user facility located at the Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab), to develop a gene-targeting, antiviral agent against COVID-19.

4 Jun 2020

Potential new immunotherapy for critical COVID-19

Researchers at the Chongqing Medical University in China have identified a cytokine that could serve as a potential candidate for treating patients with severe coronavirus disease 2019 (COVID-19).

4 Jun 2020

COVID-19 can increase stroke risk in young healthy people

Young patients with no risk factors for stroke may have an increased risk if they have contracted COVID-19, whether or not they are showing symptoms of the disease.

4 Jun 2020

Immune responsive nanoparticles for COVID-19 vaccine delivery

Analytik reports how the renowned Quadram Institute has invested in a ZetaView Nanoparticle Tracking Analyser to help them develop a new approach for vaccine delivery based on engineering the natural ability of resident gut bacteria to generate nanoparticle sized Outer Membrane Vesicles.

From Analytik Ltd 4 Jun 2020

Pre-clinical data for Celltrion’s antiviral antibody treatment shows 100-fold reduction in viral load of SARS-CoV-2

Celltrion Group today announced positive pre-clinical results for its COVID-19 antiviral antibody treatment, with data demonstrating a 100-fold reduction in the viral load of SARS-CoV-2, the virus causing COVID-19.

4 Jun 2020